↓ Skip to main content

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
1 news outlet
policy
1 policy source
twitter
8 X users
patent
1 patent
facebook
1 Facebook page
guideline
3 clinical guideline sources

Readers on

mendeley
158 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
Published in
Lancet Oncology, October 2012
DOI 10.1016/s1470-2045(12)70412-6
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 158 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Japan 3 2%
France 3 2%
Malaysia 1 <1%
United Kingdom 1 <1%
Ecuador 1 <1%
Unknown 149 94%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 28 18%
Student > Master 22 14%
Other 21 13%
Student > Bachelor 15 9%
Student > Ph. D. Student 14 9%
Other 27 17%
Unknown 31 20%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 80 51%
Agricultural and Biological Sciences 8 5%
Pharmacology, Toxicology and Pharmaceutical Science 7 4%
Nursing and Health Professions 5 3%
Biochemistry, Genetics and Molecular Biology 4 3%
Other 18 11%
Unknown 36 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 30. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 March 2024.
All research outputs
#1,688,778
of 34,536,218 outputs
Outputs from Lancet Oncology
#2,002
of 8,014 outputs
Outputs of similar age
#9,285
of 230,493 outputs
Outputs of similar age from Lancet Oncology
#20
of 101 outputs
Altmetric has tracked 34,536,218 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,014 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 39.2. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 230,493 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 101 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.